Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
33 stopped studies mapped to Malignant Anal Neoplasm and descendants · 88% state a reason
Over the 33 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT07090174 | CASCADE: Testing for Safety and Immune Effects of PDS0101, an Anti-HPV Therapy, Among… | Phase 2 | withdrawn | Jul 29, 2025 | University of California, San Diego | Study withdrawn prior to participant enrollment due to lack of study product. | Enrollment / accrual |
| NCT04234113 | Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With… | Phase 1 | terminated | Jan 21, 2020 | SOTIO Biotech AG | Due to lack of efficacy shown at the time of the interim analysis. | Efficacy / futility |
| NCT05551117 | A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant…(Tamarack) | Phase 2 | terminated | Sep 22, 2022 | MacroGenics | Business reasons | Sponsor / business decision |
| NCT02408861 | Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory… | Phase 1 | terminated | Apr 6, 2015 | National Cancer Institute (NCI) | Inadequate accrual rate | Enrollment / accrual |
| NCT02885142 | Early Rectal Cancer: Endoscopic Submucosal Dissection or Transanal Endoscopic…(MUCEM) | N/A | terminated | Aug 31, 2016 | Assistance Publique Hopitaux De Marseille | difficulties to recruit all the patients | Enrollment / accrual |
| NCT04272034 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in… | Phase 1 | terminated | Feb 17, 2020 | Incyte Corporation | A business decision was made to discontinue further enrollment. There were no safety concerns that… | Safety / toxicity |
| NCT04985357 | Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor… | — | withdrawn | Aug 2, 2021 | Travera Inc | Abandoned prior to launch. | Other (stated, no rule matched) |
| NCT03439085 | DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and… | Phase 2 | terminated | Feb 20, 2018 | M.D. Anderson Cancer Center | Project delays | Other (stated, no rule matched) |
| NCT04066894 | Sacral Nerve Stimulation in Treating Low Anterior Resection Syndrome or Fecal… | Phase 2 | terminated | Aug 26, 2019 | M.D. Anderson Cancer Center | Due to Issues Enrolling Patients | Enrollment / accrual |
| NCT05582031 | Regorafenib With Tislelizumab in Patients With Selected Mismatch…(REFIT-MSS) | Phase 2 | withdrawn | Oct 17, 2022 | Translational Research in Oncology | Study never started/ will not proceed. | Other (stated, no rule matched) |
| NCT04672980 | RTX-321 Monotherapy in Patients With HPV 16+ Tumors | Phase 1 | terminated | Dec 17, 2020 | Rubius Therapeutics | The Sponsor terminated study after dosing 3 dose groups (9 pts) and closed trial on 11/30/22.… | Other (stated, no rule matched) |
| NCT04596033 | TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy | Phase 1 | terminated | Oct 22, 2020 | Genocea Biosciences, Inc. | Business reasons | Sponsor / business decision |
| NCT02503111 | The HPV-SAVE Study Team: HPV Screening and Vaccine Evaluation in Men Who Have Sex With Men(HPV-SAVE) | N/A | terminated | Jul 20, 2015 | University Health Network, Toronto | Results from ANCHOR study showed benefit of Treatment over Surveillance in preventing anal… | Other (stated, no rule matched) |
| NCT01324141 | Topical MTS-01 for Dermatitis During Radiation and Chemotherapy for Anal Cancer | Phase 1 | terminated | Mar 28, 2011 | National Cancer Institute (NCI) | Slow, insufficient accrual and failure to meet endpoints. | Enrollment / accrual |
| NCT04499352 | A Study to Test BI 754091 Alone or in Combination With BI 836880 in People Who Have… | Phase 2 | withdrawn | Aug 5, 2020 | Boehringer Ingelheim | Not due to safety reasons (sponsor decision). | Safety / toxicity |
| NCT03942900 | Immunomonitoring and Biomarker Research in Patients With Squamous Cell Anal Carcinoma(LAND) | — | withdrawn | May 8, 2019 | Centre Hospitalier Universitaire de Besancon | Study not submitted to regulatory authorities | Other (stated, no rule matched) |
| NCT01249443 | Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors… | Phase 1 | terminated | Nov 29, 2010 | AIDS Malignancy Consortium | Inadequate accrual rate | Enrollment / accrual |
| NCT00568425 | QOL & Functional Outcomes After Combined Modality Tx for Anal CA: Comparison of… | — | terminated | Dec 6, 2007 | Stanford University | Inadequate response to Scientific Review Committee. | Other (stated, no rule matched) |
| NCT01671488 | A Phase I/II Evaluation of ADXS11-001, Mitomycin, 5-fluorouracil (5-FU) and IMRT for Anal…(276) | Phase 1 / Phase 2 | terminated | Aug 23, 2012 | Brown University | pilot data to be used for upcoming larger trial. | Other (stated, no rule matched) |
| NCT00955240 | Radiation Therapy, Cisplatin, Fluorouracil, and Cetuximab in Treating Patients With… | Phase 2 | terminated | Aug 10, 2009 | UNICANCER | Inadequate toxicity | Safety / toxicity |
| NCT00394602 | Chemoradiation-Induced Nausea and Emesis: Quality of Life | — | terminated | Nov 1, 2006 | M.D. Anderson Cancer Center | Requested by PI during yearly Continuing Review | Other (stated, no rule matched) |
| NCT03677960 | Study of Topical ABI-1968 in Subjects With Precancerous Anal Lesions Resulting From Human… | Phase 1 | terminated | Sep 19, 2018 | Antiva Biosciences | Pre-Clinical Toxicology Findings | Other (stated, no rule matched) |
| NCT00267787 | Molecular Genetic and Pathological Studies of Anal Tumors | — | terminated | Dec 21, 2005 | Stanford University | not stated | Not stated |
| NCT02407561 | Prospective Validation Study for the Proprietary Rectal and Anal Cancer Protein… | — | terminated | Apr 3, 2015 | Castle Biosciences Incorporated | Futility - unable to secure sites and samples for participation | Efficacy / futility |
| NCT00903396 | Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy… | Phase 2 | terminated | May 18, 2009 | Alliance for Clinical Trials in Oncology | Slow accrual | Enrollment / accrual |
| NCT02857608 | A Prospective, Open-Label, Multi-center Comparison of Lymphoseek Identified Lymph Nodes… | Phase 2 | withdrawn | Aug 5, 2016 | Cardinal Health 414, LLC | not stated | Not stated |
| NCT00767234 | Permission to Collect Blood Over Time for Research | — | terminated | Oct 7, 2008 | Stanford University | Accrual issues - Low Accrual | Enrollment / accrual |
| NCT01843452 | Phase II Study of Concomitant Intensity-modulated Radiotherapy Combined to Capecitabine,… | Phase 2 | terminated | Apr 30, 2013 | Centre Hospitalier Universitaire Vaudois | Poor recruitment | Enrollment / accrual |
| NCT02162641 | Study to Determine the Feasibility of Sentinel Node Biopsy in Patients With Anal Cancer(R-SeNSAR) | — | withdrawn | Jun 13, 2014 | The Christie NHS Foundation Trust | The study was terminated early as it failed to recruit. | Enrollment / accrual |
| NCT00896467 | Psychological and Emotional Impact in Patients Undergoing Treatment For Metastatic Cancer… | — | terminated | May 11, 2009 | Centre Oscar Lambret | not stated | Not stated |
| NCT00068744 | Radiation Therapy, Mitomycin, and Either Fluorouracil or Cisplatin in Treating Patients… | Phase 2 / Phase 3 | terminated | Sep 11, 2003 | European Organisation for Research and Treatment of Cancer - EORTC | low accrual | Enrollment / accrual |
| NCT01031056 | Collection of Biospecimen & Clinical Information in Patients w/ Gastrointestinal Cancers | — | withdrawn | Dec 14, 2009 | Stanford University | Change in research focus | Other (stated, no rule matched) |
| NCT00532987 | Assessment of Health Related Quality of Life in Patients Treated for Rectal Cancer | — | terminated | Sep 21, 2007 | Stanford University | not stated | Not stated |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Aug 19, 2026source: clinicaltrials